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Abstract
Background: The aim of this study is to evaluate the prognostic factors of overall survival (OS)
after haematopoietic stem cell transplant (HSCT) in acute lymphoblastic leukaemia (ALL) patients
using accelerated failure time (AFT), Cox proportional hazard (PH), and Cox time-varying
coefficient models.
Methods: 206 patients were enrolled after HSCH in Shariati Hospital between 1993 and 2007.
There was evidence of marked departures from the proportional hazards assumption with two
prognostic factors, relapse and chronic graft-versus-host disease (cGVHD) (P < .001). Performance
among AFT and Cox's models was assessed using explained variation and goodness of fit methods.
Discrimination among the exponential, Weibull, generalized gamma (GG), log-logistic, and
lognormal distributions was done using maximum likelihood and Akaike information criteria.
Results: The 5-year OS was 52% (95%CI: 47.3–56.7). Peak mortality hazard occurred at months
6–7 after HSCT followed by a decreasing trend. In univariate analysis, the data was better fitted by
GG distribution than by other distributions. Univariate analysis using GG distribution showed a
positive association between OS with acute graft-versus-host disease (aGVHD) (P = .021), no
relapse (P < .001), cGVHD (P < .001), neutrophil recovery (P < .001) and platelet recovery (P <
.001). Based on Cox PH models; however cGVHD and relapse were the predictive factors of OS
(P < .001). Multivariate analysis indicated that, OS is related to relapse (P < .001) and platelet
recovery (P = .037), where predictive power of Weibull AFT models was superior to Cox PH
model and Cox with time-varying coefficient (R2 = 0.46 for AFT, R2 = .21 for Cox PH and R2 = .34
for Cox time-varying coefficient). Cox-Snell residual shows Weibull AFT fitted to data better than
other distributions in multivariate analysis.
Conclusion: We concluded that AFT distributions can be a useful tool for recognizing prognostic
factors of OS in acute lymphoblastic leukemia patients.
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Background
Identifying prognostic factors of patients' survival time
after Hematopoietic stem cell transplant (HSCT) is of
importance not only because it enables the physicians to
detect the factors whose changes affect patients' survival
time, but also helps them to make the best decision about
patients' treatment.
Several factors are known to predict long-term survival of
acute lymphoblastic leukemia patients, including age,
white blood cells count, lactic dehydrogenate level, kary-
otype, stage of the disease at the time of the transplant,
Cyclosporin for preventing graft-versus-host disease and
donor-recipient sex combination[1,2]. The role of some
of this prognostic factors such as acute graft-versus-host
disease(aGVHD), chronic graft-versus-host dis-
ease(cGVHD), age, sex are controversial [2-6], for instance
aGVHD was reported a significant factor for survival after
HSCT [4,6], whereas it was not a predictive factor in other
studies[5,7]. These differences may be due to a methodo-
logical issue.
Prognostic factors of acute leukemia after HSCT are
already identified by using nonparametric survival meth-
ods such as Kaplan-Meier and Cox Proportional Hazard
(PH) in many studies[1,8-13]; the latter is used when the
effect of covariates on the hazard ratio is desired. Review
of literature shows the extensive use of the Cox PH regres-
sion model for hazard rate or instantaneous risk of a given
event [14,15]; however, the basic and the most important
assumption underlying this model is proportionality of
hazard rates, which may not be held in some situations.
Where PH assumption is not met, it is improper to use
standard Cox PH model as it may entail serious bias and
loss of power when estimating or making inference about
the effect of a given prognostic factor on mortality [15-
18]. A review of survival analysis in cancer journals reveals
that only 5% of all studies using the Cox PH model con-
sidered the underline assumption[14].
Recently, AFT models as parametric models have attracted
considerable attention, because not only they do not need
PH assumption but also thanks to availability of standard
methods such as Maximum Likelihood (ML), parameter
estimation and testing can be done readily[18].
When survival time has a specific statistical distribution,
the statistical power of parametric survival models is
higher than nonparametric or semi-parametric survival
models. The exponential, Weibull, log-logistic, lognormal
and the generalized gamma (GG) are among parametric
distributions commonly used for studying survival time
analysis. Survival estimates obtained from parametric sur-
vival models typically yield plots that are more consistent
with a theoretical survival curve [17].
Like Cox PH model, parametric survival models can be
used in regression forms. The interpretations of parame-
ters for AFT models are also different from Cox PH mod-
els. The AFT assumption is applicable for a comparison of
survival time whereas the PH assumption is applicable for
the comparison of hazards[18,19].
Since recently AFT models have not been used very often
and the few usage of these models are found in kidney
transplant studies[20,21], based on our knowledge, it has
not been used to recognize the prognostic factors of acute
leukemia patients so far. In this Paper, we tried fitting AFT
models, chose the one with the best fitness and used it to
determine prognostic factors for survival after HSCT in
acute leukemia patients. We did also compare the results
of AFT models with Cox PH and Cox time-varying coeffi-
cients models.
Methods
Data Collection and Patient Selection
Data on patients who underwent bone marrow or periph-
eral-blood transportation from HLL identical siblings
were obtained from the Hematology-Oncology and Stem
Cell Transplantation Research Center at Shariati Hospital,
Tehran, Iran. Transplantations were performed between
Oct 17, 1993 and Jan 31, 2007.
All patients received a BuCy regimen (busulfan 4 mg/kg/
day orally on days-6 to-3 and cyclophosphamide 60 mg/
kg/day by intravenous infusion on days-2 to -1) for condi-
tioning therapy with subsequent infusion of donor mar-
row cells on day 0. For graft-versus-host disease (GVHD)
prophylaxis all patients received conventional Protocol
Cyclosporin 3 mg/kg/day IV from days-2 and methotrex-
ate 10 mg/m2 day +1 and 6 mg/m2 on days 3, 6 and 11.
We changed Cyclosporin to oral formulation when oral
intake was possible.
All patients' records were reviewed for the occurrence of
adverse events including GVHD and regimen-related tox-
icities. There were 206 patients eligible for this longitudi-
nal study. Patients in this study were in the age range of 2–
56 years old and had received a HLA-matched marrow
transplant. The median follow up time after transplanta-
tion was about 1.5 years.
Definition of Endpoints
Platelet recovery was defined by a count of at least 20,000
platelets per micro liters, unsupported by transfusion for
seven days.
Hematopoietic recovery
Neutrophil recovery was defined by an absolute neu-
trophil count of at least 500 cells per cubic millimeter in
three consecutive days.Journal of Experimental & Clinical Cancer Research 2008, 27:74 http://www.jeccr.com/content/27/1/74
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GVHD
The incidence of acute GVHD (aGVHD) was determined
in all patients. Acute GVHD was graded according to the
Seattle criteria [13,22]. The aGVHD grade of 1,2,3,4 was
defined for having aGVHD. Chronic GVHD (cGVHD) was
defined according to standard criteria [13,22]. The inci-
dence of chronic GVHD (cGVHD) was determined in
patients who survived for at least 90 days [13,23,24].
Relapse
Relapse was defined as a recurrence of leukemia con-
firmed by cytology.
Survival
Overall Survival (OS) was defined as the time interval
between HSCT and death of any cause related to acute
leukemia or censoring. Censoring was defined as being
alive at the last follow-up. According with the specific
goals of the analysis, we did not classify the events
(deaths) according to theirs reasons.
Time ratios (TR)
AFT model coefficients are most intuitively expressed in
the exponential form, a TR > 1 associates with a prolonged
survival time whereas a TR < 1 is associated with a
decrease in survival time[25].
Statistical Analysis
The probability of OS was estimated using Kaplan-Meier
estimator. Confidence intervals were calculated via Log
transformation[18]. The quantile-quantile(QQ) plot was
used to check the adequacy of AFT assumption[18].
AFT models such as the exponential Weibull, Log-Logistic,
lognormal and Generalizes Gamma (GG) distributions
were used for finding the best distribution fitted to time to
event after HSCT. To find the best fitted model among GG
family distributions such as; the Exponential, Weibull,
lognormal and GG we used maximum likelihood (ML)
and Akaike information criteria(AIC) as well as using
graphical methods, namely Cox-Snell residuals [16-19].
Discrimination among distributions of the GG family was
done using likelihood-ratio chi-square test[19]. Akaike
information criteria was use to compare the best fitted
model in the GG family with log-logistic distribution.
Adequacy of the AFT models was gauged by a liner func-
tion of cumulative hazard rate versus appropriate function
of survival time: for exponential, a plot of -
log&#x015C;(t) versus t, for Weibull, a plot of log [-
log&#x015C;(t)] versus log t, for log-logistic, a plot of log
[(1-&#x015C;(t))/&#x015C;(t)] versus log t [16,18,19].
Deviance residuals and Martingale residuals were consid-
ered for checking outliers and influential observations in
models[18,19,26].
Model performance among AFT and Cox's was achieved
using the explained variation and goodness of fit
test(GOF) methods[16,27]. Conditional distributions of
parametric (AFT models) survival time models were esti-
mated by including different covariates in the models.
AFT models were used for finding prognostic factors of
survival after HSCT. PH assumption was checked using
graphical methods(log cumulative hazard rate versus sur-
vival time), score residuals, the scaled Schoenfeld residu-
als and time-depended variable procedures [18,19,28].
Smoothed hazard function was estimated using Kernel
smoothing method (Epanechnikov function)[16,29]. P-
value less than .05 was considered significant. Analyses
were done using STATA ver. 8.
Results
General Description
One hundred and thirty nine (67.5%) of patients and
eighty five (41.3%) of donors were female. Table 1 shows
the characteristics of 206 patients who were included in
the study. Based on Kaplan-Meier curve, the 5-year-sur-
vival rate was 52 % (95% CI: 47.3–56.7) (Figure. 1), for
patients in the first complete remission (CR1) this rate
was estimated as 65% (CI 95%: 60.1–69.9).
The shape of hazard function for mortality revealed a peak
at 6–7 months after HSCT followed by a decreasing trend
as hazard of dying in the first 6 months after transplanta-
tion was higher than the second six months (Figure 2).
The shape of hazard function in Figure 2 suggests the
appropriateness of the generalized gamma, log normal or
log-logistic distributions. The gamma and log normal are
more preferable when hazard rises to a peak before
decreasing.
In the absence of covariates, GG is the best fitted mode
Among AFT models (it has the smallest AIC) (table 2);
therefore the values of goodness-of-fit other distributions
were compared to GG distribution.
Since Exponential, Weibull and log-normal distributions
are nested in GG distribution, the difference between Log-
likelihood (LL) of GG model and its nested model multi-
plying by 2 yields the following likelihood-ratio chi-
square statistics:
X2 = 48.8, df = 2, P = < 0.001, Exponential vs. GG
X2 = 27.2, df = 1, P = < 0.001, Weibull vs. GGJournal of Experimental & Clinical Cancer Research 2008, 27:74 http://www.jeccr.com/content/27/1/74
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X2 = 5.8, df = 1, P = .016, Lognormal vs. GG
Likelihood-ratio chi-square statistics and AIC show GG
fits the data better than exponential, Weibull, log-normal
distributions. Moreover in the absence of covariates, AIC
showed that GG model was a better fit than log-logistic
distribution (Table 2).
Prognostic Factors of Survival after HSCT, Univariate 
Analysis
Quantile-quantile(QQ) plots provide the adequacy of
AFT models in univariate analysis. We show QQ plot for
relapse in figure 3. Maximum likelihood (ML), AIC and
graphical methods all showed that, in univariate analysis,
the GG model fitted the data better than other AFT models
Table 1: Patients and Transplants Characteristic
Characteristic Frequency (%)
Donor-recipient sex match-no. (%)
Male-male 85(41.3)
Male-female 54(26.2)
Female-male 36(17.5)
Female-female 31(15)
Age Mean(SD) 22.5(8.73)
Age(years), Median(range) 20(2–51)
Donor age, Median(range) 21(2–55)
Age group – no. (%)
< 15 yr 37(18)
16–20 yr 72(35)
21–30 yr 64(31.1)
31–40 yr 22(10.7)
> 40 yr 11(5.3)
Outcomes-no. (%)
Death 76(39.9)
Relapse 59(28.6)
aGVHD 136(77.7)
cGVHD 34(24.1)
Platelet recovery 141(75.0)
Neutrophil recovery 167(85.6)
Time of aGVHD-day
Mean(SD) 13.3(16.5)
Median 9
Range 3–90
Time of cGVHD-day
Mean(SD) 160.26(73.4)
Median 140
Range 91–327
Time of relapse-day
Mean(SD) 580(555)
Median 412
Range 10–2661
Time of platelet recovery-day
Mean(SD) 20.8(19.2)
Median 17
Range 1–165
Time of neutrophil recovery-day
Mean(SD) 13.46(12.8)
Median 11
Range 1–160
Follow up-month
Median 16
range 3–89
aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-
versus-host disease
Kaplan-Meir estimated survival after transportation for  patients diagnosed with acute lymphoblastic leukemia Figure 1
Kaplan-Meir estimated survival after transportation 
for patients diagnosed with acute lymphoblastic 
leukemia.
Smoothed death hazard in acute lymphoblastic leukemia  patients after transplantation Figure 2
Smoothed death hazard in acute lymphoblastic 
leukemia patients after transplantation.Journal of Experimental & Clinical Cancer Research 2008, 27:74 http://www.jeccr.com/content/27/1/74
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(Table 2). Proceeding with GG model, univariate analysis
showed that there is a significant association between OS
and relapse, aGVHD, cGVHD, neutrophil recovery and
platelet recovery (Table 3), whilst Cox PH revealed a sig-
nificant association between OS and both relapse and
platelet recovery (Table 3). Table 3 shows that there is a
strong correlation between OS and leukemia recurrence
after transplantation (P < .001, Time Ratios (TR) = 10).
Median OS in patients who have had relapse after trans-
plantation was about 10 times shorter than others. The
assumption of proportionality was not met for relapse in
the Cox PH model (P = < .0001) (Figure 4). Based on our
results, the hazard of death in patients with recurred
relapse is 4.8 times higher than other patients (Table 3).
The constancy of hazard ratio over time is not unrealistic,
given that PH assumption is not met for the model (Figure
4).
Incidence of cGVHD, among patients who survived for 90
days or longer after transplantation was 24.1%. For these
patients there was a significant association between
cGVHD and OS (P < .001 TR = 5), indicating that median
OS was about 5 times longer in the acute leukemia
patients with cGVHD compare to those without it (table
3); However since the assumption of proportionality was
not met for cGVHD in the Cox PH model (P = < .003, Fig-
ure 5), the interpretation of HR may be questionable.
Prognostic Factors of Survival after HSCT, Multivariate 
Analysis
Variables with significance level less than 0.2 in univariate
analysis were considered in the multivariate models.
Based on AIC criteria (with the smallest AIC as the best),
the model including relapse, platelet recovery, neutrophil
recovery, aGVHD and cGVHD is the best for prediction of
OS (final model in table 2).
Weibull distribution has the smallest AIC; therefore it is
the best fitted model on data. Goodness-of-fit of exponen-
tial distribution versus Weibull distribution must be
Table 2: Discrimination among Distributions Using Maximum Likelihood (LL) and Akaike Information Criteria (AIC) (n = 206)
GG family
Model No. Variables name Goodness of fit criteria Exponential Weibull Log normal GG Log-logistic Best model
1 Without covariate -LL
AIC
251.7
503.4
240.9
483.8
233.1
468.2
227.3
458.6
236.6
475.2
GG
2a G V H D - L L
AIC
231.1
464.2
218.6
441.2
211.1
426.2
202.6
411.2
214.7
423.4
GG
3c G V H D - L L
AIC
225.7
453.4
212.5
429.0
204.4
412.8
195.1
396.2
208.1
420.2
GG
4 Platelet
recovery
-LL
AIC
240.6
438.2
231.0
466.0
223.2
450.4
214.4
434.8
227.2
458.4
GG
5R e l a p s e - L L
AIC
216.2
434.4
213.2
430.4
219.3
442.6
210.5
427.0
218.0
440.0
GG
6 Neutrophil
recovery
-LL
AIC
248.5
499.0
238.2
480.4
230.2
464.4
218.9
443.8
234.2
472.4
GG
7* aGVHD, cGVHD, relapse, platelet 
recovery, neutrophil recovery
-LL
AIC
181.2
372.4
177.9
367.8
179.1
370.2
178.1
370.2
179.1
370.2
Weibull
8 aGVHD, cGVHD, relapse, platelet 
recovery, neutrophil recovery 
patients' age and sex
-LL
AIC
180.4
374.8
177.2
370.4
177.6
371.2
177.4
372.8
178.0
372.0
Weibull
*Final Model, GG; Generalized Gamma, cGVHD; chronic graft-versus-host disease. AIC = -2LL+2P, where p is the number of parameters in the 
model, Model number 7 is the best fitted model because it has the smallest AIC.
Table 3: Prognostic Factors of OS in Univariate Analysis Using Generalized Gamma and Cox Model (n = 206).
Generalized Gamma Cox PH
Characteristics TR (95% CI) p-value HR (95% CI) p-value proportional assumption p-value
Relapse(yes vs. no) 10(3.2–21.27) < .001 4.79(2.99 7.67) < .001 Not met < .001
aGVHD(yes vs. no) 2.29(1.13–4.71) .021 .82(.46 2.03) .49 Met .68
cGVHD(yes vs. no) 5(2.27–10.71) < .001 .53(.27 1.05) .072 Not Met .004
Platelet recovery(yes vs. no) 3.39(1.19–6.1) < .001 .51(.31 .82) .006 Met .48
Neutrophil recovery(yes vs. no) 3.60(1.90–6.9) < .001 .65(.35 1.21) .18 Met .11
aGVHD; acute graft-versus-host disease, cGVHD; chronic graft-versus-host disease, PH; proportional hazard, HR; hazard ratio, TR; time ratio
Note: the corresponding regression coefficients in the above models can be obtained by taking logarithm of time ratio and hazard ratio.Journal of Experimental & Clinical Cancer Research 2008, 27:74 http://www.jeccr.com/content/27/1/74
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rejected(X2 = 6.6, df = 1, P = .01). Figure 6 shows that, plot
of Cox-Snell residuals versus the Nelson-Aalen estimator
or the cumulative hazard of the residuals is straight line
with slop one indicating adequacy of the fitted Weibull
distribution.
Nevertheless, since PH assumption was not met for this
model (test for scaled Schoenfeld residuals; for relapse: X2
QQ plot for time to death of acute lymphoblastic leukemia  patients after transplantation grouped according to relapse  development Figure 3
QQ plot for time to death of acute lymphoblastic 
leukemia patients after transplantation grouped 
according to relapse development.
Log(-log(survival) curve for time to death of acute lymphob- lastic leukemia patients after transplantation grouped accord- ing to relapse development Figure 4
Log(-log(survival) curve for time to death of acute 
lymphoblastic leukemia patients after transplanta-
tion grouped according to relapse development.
Log(-log(survival) curve for time to death of acute lymphob- lastic leukemia patients after transplantation grouped accord- ing to cGVHD development Figure 5
Log(-log(survival) curve for time to death of acute 
lymphoblastic leukemia patients after transplanta-
tion grouped according to cGVHD development.
Cox-Snell residuals to assess the fit of the Weibull model for  time to death of acute lymphoblastic leukemia patients after  transplantation Figure 6
Cox-Snell residuals to assess the fit of the Weibull 
model for time to death of acute lymphoblastic 
leukemia patients after transplantation.Journal of Experimental & Clinical Cancer Research 2008, 27:74 http://www.jeccr.com/content/27/1/74
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= 26.91 P = .000, for cGVHD: X2 = 8.28, P = .004, global
test: X2 = 42.5, df = 5 P < .001) the interpretation of hazard
ratios (HRs) of Cox model in Table 4 may be questiona-
ble. When PH assumption is not met for a model, we can
usually use AFT or Cox model with time-varying covari-
ates. Explained variation, AIC criteria and graphical meth-
ods (Figure 6) show that the Weibull AFT is the best
model comparing with Cox PH and Cox with time-vary-
ing coefficients. Table 4 shows interaction between time
and both cGVHD and relapse in a Cox model with time-
varying coefficients, so their hazard ratios cannot be inter-
preted separately.
Discussion
Our objective was to identify prognostic factors of OS
using parametric (AFT models) and semi-parametric
methods (Cox's models). Peak mortality hazard occurred
at months 6–7 after transplantation with a decreasing rate
afterwards. In a model without any covariate and in uni-
variate analysis GG distribution fitted the data better than
other parametric survival models such as the exponential,
Weibull, log-normal, log-logistic distributions (table 2). It
has been shown that hazard function in the GG distribu-
tion can take a wide variety of shapes [16], one of which
is when it reaches a maximum and then decreases [30]. To
our knowledge, no other study of this type has ever
worked on prognostic factors of OS in ALL patients using
GG distribution.
In many researches, Cox PH regression models were used
to consider prognostic factors of OS in acute leukemia
patients [11,12,21,24,31,32]. The results of this research
show that Cox PH models may fail to identify prognosis
factors of OS in acute lymphoblastic leukemia patients. As
our results indicated, in univariate analysis, neutrophil
recovery, platelet recovery and aGVHD were significant
prognostic factors of OS using GG distribution whereas
they failed to be significant prognostic factors when using
Cox PH model (Table 3). However, even if the assump-
tion of PH holds, we may still get different results with
these two models. It seems that patients, who have neu-
trophil recovery, survive longer comparing to the patients
without it. Based on our findings, the result of GG distri-
bution makes more sense and looks more reasonable than
Cox PH model.
For the final model of the multivariate analysis, the haz-
ard ratio for covariates may not have a clear interpretation
as the assumption of PH was not held Here clearly using
AFT survival models is advantageous over Cox PH model
as it does not require the assumption of PH (9). Moreover,
AFT models not only can specify a direct relation between
the logarithm of survival time and a set of explanatory var-
iables, but also permits a clearer interpretation of the
effect of each covariate on survival, allowing to estimate
the median event times.
Maximum likelihood, AIC (table 1), and Cox-Snell resid-
ual plots (Figure 6 show Weibull AFT is the best fitted
model among AFT models. There are two types of Weibull
model: Weibull AFT and Weibull PH; but only for the lat-
ter is the assumption of PH indispensable; thereby when
it does hold we can use either Weibull AFT, Weibull PH or
Cox PH[16,17]. In Table 4, explained variations show that
predictive power of Weibull AFT is higher than Cox PH
and the Cox model with time-varying coefficients.
Usually when PH assumption dose not hold, alternatives
are stratified Cox, Cox with time-varying coefficients, AFT
models, additive hazard models, and proportional odds
models[18,33]. Since PH assumption was not met for the
two covariates cGVHD and relapse, following stratifica-
tion on these covariates not only decreases the power of
the analysis (due to small sample size within strata) but
also prevents the estimation of effects of the stratified var-
iables. Likewise log-logistic model, the one with the char-
Table 4: Prognostic Factors of OS in Multivariate Analysis Using AFT and Cox's Models (n = 206).
Weibull AFT Cox PH Cox with time-varying coefficients
Characteristics Time ratio(95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Relapse(yes vs. no) .082(.039 .17) < .001 5.2(3.1 8.94) < .001 .69(.25 1.8) .062
aGVHD(yes vs. no) .95(.45 2.03) .91 1.09(.61 1.95) .76 .96(.53 1.74) .90
cGVHD(yes vs. no) 1.52(.62 3.72) .35 .71(.35 1.43) .34 .16(.04 .62) .008
Platelet recovery(yes vs. no) 2.37(1.05 5.32) .037 .52(.28 .96) .039 .53(.28 1.03) 062
Neutrophil recovery(yes vs. no) 2.71(.62 11.85) .184 .46(.14 1.44) .187 .39(.12 1.24) .12
Ti *cGVHD 1.006(1.002 1.011) .003
Ti *relapse 1.012(1.006 1.019) < .001
Explained variation(R2). 4 6 . 2 1 . 3 4
aGVHD; acute graft-versus-host disease, cGVHD; chronic graft-versus-host disease, AFT; accelerated failure time, PH; proportional hazard, HR; 
hazard ratio, Ti; survival time.
Note: the corresponding regression coefficients in the above models can be obtained by taking logarithm of time ratio and hazard ratio.Journal of Experimental & Clinical Cancer Research 2008, 27:74 http://www.jeccr.com/content/27/1/74
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acteristics of both AFT and proportional odds models[18]
did not show reasonable fit to our data suggesting propor-
tional odds models are not suitable.
When intermediate events have effect on survival time it is
suggested to use the multistate models to describe disease
progress. AFT and Cox PH models are among those that
can be implemented in such situations [34,35].
It is worth noting that, choosing appropriate model for
finding prognostic factors of survival is not an easy task, as
checking the goodness of fit could be quite time consum-
ing. Fortunately, there are many methods for checking the
goodness of fit of the models[14,15,15,15,16,19,30,36].
We checked our models using some of these methods.
These methods could helpfully guide us to come up with
the best model for analysis of data.
In our study, based on Kaplan-Meier curves, five-year sur-
vival rate in ALL patients at CR1 disease stage was esti-
mated to be 65% (CI 95%: 60.1–69.9). The Center of
International Blood and Marrow Transplant Research
(CIBMTR) and the National Marrow Donor Program
(NMPD) has reported 65% survival rates in ALL patients
[37], showing that the patients of this study may be a
good candidate of all acute lymphoblastic leukemia
patients.
The multivariate analysis using the Weibull AFT and Cox
models show that relapse and cGVHD are two independ-
ent prognostic factors, with the adverse effect of relapse on
patients OS.
Results showed that, cGVHD developed in 24.1% of ALL
patients. In adults, the reported incidence of cGVHD was
ranging between 30% and 50% of HLA-identical sibling
transplant recipients[38]. In our study developed cGVHD
had a positive significant effect on prognosis of ALL
patients; Moreover there are some studies reporting the
effect of cGVHD on OS [39,40].
Conclusion
In summary, the results of the current study suggest that
when implementing survival analysis in cancer research
centers, using the PH model may not be the optimum
approach. It is important to identify the distribution of OS
and to seek for an appropriate model like AFT models for
data analysis. The results from an AFT model are easily
interpreted provide a more appropriate description of sur-
vival time in many researches, and should be considered
as an alternative to the Cox PH model.
The choice of the appropriate model will certainly lead to
identify more reliable and precise prognostic factors and
thereby help to have a more effective treatment program.
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